The effect of hypertension and antihypertensive therapies on the course of COVID-19 infection: Turkish national health system data

Basit Öğe Kaydı
dc.authoridÜlgü, Mustafa Mahir/0000-0003-0825-1851
dc.authorscopusid8570900600
dc.authorscopusid6603926071
dc.authorscopusid56216377800
dc.authorscopusid56275070300
dc.authorscopusid9736922500
dc.authorscopusid24471549000
dc.authorscopusid57218631005
dc.authorwosidÜlgü, Mustafa Mahir/GQQ-2809-2022
dc.contributor.authorÖzkan, Gülsüm
dc.contributor.authorUlusoy, Şükrü
dc.contributor.authorErdem, Yunus
dc.contributor.authorAltun, Bülent
dc.contributor.authorYılmaz, Rahmi
dc.contributor.authorAta, Naim
dc.contributor.authorBirinci, Şuayip
dc.date.accessioned2023-04-20T08:01:15Z
dc.date.available2023-04-20T08:01:15Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAim The effect of hypertension (HT) and antihypertensive therapies such as renin-angiotensin-aldosterone system (RAAS) blockers on the disease course in COVID-19 patients is controversial. The purpose of this study was to evaluate the effect of HT and antihypertensive therapies on the course of COVID-19 disease. Method The age, sex, comorbid diseases, and antihypertensive therapies of 132,790 patients with positive COVID-19 real-time transcriptase polymerase chain reaction (RT-PCR) tests in the Turkish Health Ministry National COVID-19 database between 11 March and 31 May 2020, were examined and analyzed. Results Forty-one percent of the 132,790 patients in this study (median age: 40, 47.3% female) were hospitalized for treatment, and 4.5% were followed-up in the intensive care unit (ICU). The most frequent comorbid disease, at 19.5%, was HT (n = 25,863). Mortality was determined in 4.9% of HT patients and 1.9% of non-HT patients (p < .001). HT, age, and male gender emerged as independent predictors of hospitalization and admission to the ICU, while HT was not a predictor of mortality. In addition, no adverse effect of any antihypertensive treatment, including RAAS inhibitors, on mortality was detected. Conclusion Based on Turkish national data, HT is common in COVID-19 patients, but does not appear to be an independent predictor of mortality, and no adverse effect of RAAS inhibitors on COVID-19-related mortality was observed.
dc.identifier.doi10.1080/10641963.2022.2071923
dc.identifier.endpage506
dc.identifier.issn1064-1963
dc.identifier.issn1525-6006
dc.identifier.issue6en_US
dc.identifier.pmid35510709
dc.identifier.scopus2-s2.0-85132633662
dc.identifier.scopusqualityQ3
dc.identifier.startpage502
dc.identifier.urihttps://doi.org/10.1080/10641963.2022.2071923
dc.identifier.urihttps://hdl.handle.net/20.500.11776/10832
dc.identifier.volume44
dc.identifier.wosWOS:000791135400001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÖzkan, Gülsüm
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofClinical and Experimental Hypertension
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHypertension
dc.subjectCovid-19
dc.subjectAntihypertensive
dc.subjectMortality
dc.subjectRaas Blocker
dc.subjectOutcomes
dc.titleThe effect of hypertension and antihypertensive therapies on the course of COVID-19 infection: Turkish national health system data
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
10832.pdf
Boyut:
462.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu